Maturing iPSC-Derived Cardiomyocytes

Tang, Bor Luen

doi:10.3390/cells9010213

Cited by 12 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…for the ryanodine receptor RyR2. 122 More recently, the application of physical and mechanical stimuli, culturing in 3D settings or fatty acids, has been shown to provide a powerful strategy to render more developmentally mature iPSC-CMs. 123,124 Animal studies were performed to further explore the potential of these differentiated iPSCs.…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Combining stem cells in myocardial infarction: The road to superior repair?

Beliën

Evens

Hendrikx

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Myocardial infarction irreversibly destroys millions of cardiomyocytes in the ventricle, making it the leading cause of heart failure worldwide. Over the past two decades, many progenitor and stem cell types were proposed as the ideal candidate to regenerate the heart after injury. The potential of stem cell therapy has been investigated thoroughly in animal and human studies, aiming at cardiac repair by true tissue replacement, by immune modulation, or by the secretion of paracrine factors that stimulate endogenous repair processes. Despite some successful results in animal models, the outcome from clinical trials remains overall disappointing, largely due to the limited stem cell survival and retention after transplantation. Extensive interest was developed regarding the combinational use of stem cells and various priming strategies to improve the efficacy of regenerative cell therapy. In this review, we provide a critical discussion of the different stem cell types investigated in preclinical and clinical studies in the field of cardiac repair. Moreover, we give an update on the potential of stem cell combinations as well as preconditioning and explore the future promises of these novel regenerative strategies.

show abstract

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Combining stem cells in myocardial infarction: The road to superior repair?

Beliën

Evens

Hendrikx

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Commonly, adult fibroblasts are reprogrammed into iPSCs through the activation of alkaline phosphatase, silencing of somatic-specific expression, expression of SSEA1, and progressive silencing of exogenous genes with upregulation of Oct4 and Nanog ( Teshigawara et al, 2017 ). However, these CMs are closer to an immature stage in terms of marker expression, ultrastructural features, metabolic signature, and electrophysiological properties ( Tang, 2020 ). First, the origin of somatic cells is a determinant of iPSC-CM maturation ( Pianezzi et al, 2020 ).…”

Section: Cell Reprogrammingmentioning

confidence: 99%

“…Additionally, the application of iPSC-CMs is highly affected by the purification process because tumors can form during in vitro culture of iPSCs that increase the malignant risks to in vivo application ( Tohyama et al, 2013 ). To overcome the purification obstacles, a distinct metabolic flow technology has been designed to enable large-scale purification through glucose depletion and lactate supplementation because the mature iPSC-CMs have a higher oxygen consumption rate with increased mitochondrial maturity ( Tohyama et al, 2013 ; Tang, 2020 ).…”

Section: Cell Reprogrammingmentioning

confidence: 99%

Bioengineering Technologies for Cardiac Regenerative Medicine

Chingale

Zhu

Cheng

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiac regenerative medicine faces big challenges such as a lack of adult cardiac stem cells, low turnover of mature cardiomyocytes, and difficulty in therapeutic delivery to the injured heart. The interaction of bioengineering and cardiac regenerative medicine offers innovative solutions to this field. For example, cell reprogramming technology has been applied by both direct and indirect routes to generate patient-specific cardiomyocytes. Various viral and non-viral vectors have been utilized for gene editing to intervene gene expression patterns during the cardiac remodeling process. Cell-derived protein factors, exosomes, and miRNAs have been isolated and delivered through engineered particles to overcome many innate limitations of live cell therapy. Protein decoration, antibody modification, and platelet membranes have been used for targeting and precision medicine. Cardiac patches have been used for transferring therapeutics with better retention and integration. Other technologies such as 3D printing and 3D culture have been used to create replaceable cardiac tissue. In this review, we discuss recent advancements in bioengineering and biotechnologies for cardiac regenerative medicine.

show abstract

“…Therefore, increasing research attention has been focused on the in vitro differentiation of iPSCs in the laboratory setting, to obtain the desired cell type, which can then be applied to the patient. Notably, the differentiation of murine and human iPSCs into cardiomyocytes (iPSC-CMs) has been extensively described and is now standard practice in laboratories worldwide [ 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 ].…”

Section: Ipsc Generation and Cardiac Differentiationmentioning

confidence: 99%

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

2021

View full text Add to dashboard Cite

Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells’ stage of differentiation, origin, and technical application.

show abstract

Maturing iPSC-Derived Cardiomyocytes

Abstract: Cardiovascular disease is a major cause of mortality worldwide [...]

Cited by 12 publications

References 15 publications

Combining stem cells in myocardial infarction: The road to superior repair?

Combining stem cells in myocardial infarction: The road to superior repair?

Bioengineering Technologies for Cardiac Regenerative Medicine

iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams

Contact Info

Product

Resources

About